Evidence map›Paper›PMID 32820216›Full record

ArticleScientific reports2020

RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.

W L William Chang, Jesse D Deere, Hung T Kieu, Luis D Castillo, Kawthar Machmach, Xiaoying Shen, Georgia D Tomaras, Barbara L Shacklett, Peter A Barry, Dennis J Hartigan-O'Connor and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. HIV T-cell immunogen design and delivery.Current opinion in HIV and AIDS · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

W L William ChangCenter for Immunology and Infectious Diseases, Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Jesse D DeereDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Hung T KieuCenter for Immunology and Infectious Diseases, Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Luis D CastilloCenter for Immunology and Infectious Diseases, Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Kawthar MachmachCalifornia National Primate Research Center, University of California, Davis, CA, USA.
Xiaoying ShenDepartment of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Georgia D TomarasDepartment of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Barbara L ShacklettDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Peter A BarryCenter for Immunology and Infectious Diseases, Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
Dennis J Hartigan-O'ConnorCalifornia National Primate Research Center, University of California, Davis, CA, USA. dhartigan@ucdavis.edu.
Ellen E SpargerDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA, USA. eesparger@ucdavis.edu.
University of California, Davis · USDuke Medical Center · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
UC Davis Biostatistics CoreP01AI131568 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STEVENSON, MARIO · 2017 to 2021
$7.1M
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulationR01AI143554 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2018 to 2022
$4.5M
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand SequencesR01DE021273 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BARRY, PETER A, SHACKLETT, BARBARA L. · 2011 to 2015
$3.0M
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulationR01AI150554 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2020 to 2023
$3.0M
Development and Immunogenicity of Attenuated RhCMVdelta10 Vaccine VectorsR21AI088471 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BARRY, PETER A, SPARGER, ELLEN ELIZABETH · 2010 to 2011
$419k
NIAID NIH HHS P01 AI131568NIAID NIH HHS R01 AI143554NIAID NIH HHS R01 AI150554NIAID NIH HHS R21 AI088471NIDCR NIH HHS R01 DE021273NIH HHS HHSN27201100016CNIH HHS P51 OD011107
6 · The paper itself

Abstract

Rhesus cytomegalovirus (RhCMV) strain 68-1-vectored simian immunodeficiency virus (RhCMV/SIV) vaccines are associated with complete clearance of pathogenic SIV challenge virus, non-canonical major histocompatibility complex restriction, and absent antibody responses in recipients previously infected with wild-type RhCMV. This report presents the first investigation of RhCMV/SIV vaccines in RhCMV-seronegative macaques lacking anti-vector immunity. Fifty percent of rhesus macaques (RM) vaccinated with a combined RhCMV-Gag, -Env, and -Retanef (RTN) vaccine controlled pathogenic SIV challenge despite high peak viremia. However, kinetics of viral load control by vaccinated RM were considerably delayed compared to previous reports. Impact of a TLR5 agonist (flagellin; FliC) on vaccine efficacy and immunogenicity was also examined. An altered vaccine regimen containing an SIV Gag-FliC fusion antigen instead of Gag was significantly less immunogenic and resulted in reduced protection. Notably, RhCMV-Gag and RhCMV-Env vaccines elicited anti-Gag and anti-Env antibodies in RhCMV-seronegative RM, an unexpected contrast to vaccination of RhCMV-seropositive RM. These findings confirm that RhCMV-vectored SIV vaccines significantly protect against SIV pathogenesis. However, pre-existing vector immunity and a pro-inflammatory vaccine adjuvant may influence RhCMV/SIV vaccine immunogenicity and efficacy. Future investigation of the impact of pre-existing anti-vector immune responses on protective immunity conferred by this vaccine platform is warranted.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytomegalovirusGene Products, gagHumansImmunity, InnateInterferon-gammaMacaca mulattaSimian Immunodeficiency VirusViral LoadViral VaccinesAdjuvants, ImmunologicAntibodies, ViralGene Products, gagInterferon-gammaViral Vaccines

Identifiers

PMID32820216
PMCPMC7441386
OpenAlexW3060831974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.